Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis | Demyelinating Disorders | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.108.182. Please contact the publisher to request reinstatement.
[Skip to Navigation Landing]
Original Contribution
December 20, 2006

Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis

Author Affiliations
 

Author Affiliations: Departments of Nutrition (Ms Munger and Dr Ascherio) and Epidemiology (Dr Ascherio), Harvard School of Public Health, and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School (Dr Ascherio), Boston, Mass; Division of Preventive Medicine, Walter Reed Army Institute of Research, Silver Spring, Md (Dr Levin); Departments of Pediatrics, Biochemistry, and Molecular Biology, Medical University of South Carolina, Charleston (Dr Hollis); and Department of the Navy, Secretary of the Navy Council of Review Boards, Washington, DC (Dr Howard).

JAMA. 2006;296(23):2832-2838. doi:10.1001/jama.296.23.2832
Abstract

Context Epidemiological and experimental evidence suggests that high levels of vitamin D, a potent immunomodulator, may decrease the risk of multiple sclerosis. There are no prospective studies addressing this hypothesis.

Objective To examine whether levels of 25-hydroxyvitamin D are associated with risk of multiple sclerosis.

Design, Setting, and Participants Prospective, nested case-control study among more than 7 million US military personnel who have serum samples stored in the Department of Defense Serum Repository. Multiple sclerosis cases were identified through Army and Navy physical disability databases for 1992 through 2004, and diagnoses were confirmed by medical record review. Each case (n = 257) was matched to 2 controls by age, sex, race/ethnicity, and dates of blood collection. Vitamin D status was estimated by averaging 25-hydroxyvitamin D levels of 2 or more serum samples collected before the date of initial multiple sclerosis symptoms.

Main Outcome Measures Odds ratios of multiple sclerosis associated with continuous or categorical levels (quantiles or a priori–defined categories) of serum 25-hydroxyvitamin D within each racial/ethnic group.

Results Among whites (148 cases, 296 controls), the risk of multiple sclerosis significantly decreased with increasing levels of 25-hydroxyvitamin D (odds ratio [OR] for a 50-nmol/L increase in 25-hydroxyvitamin D, 0.59; 95% confidence interval, 0.36-0.97). In categorical analyses using the lowest quintile (<63.3 nmol/L) as the reference, the ORs for each subsequent quintile were 0.57, 0.57, 0.74, and 0.38 (P = .02 for trend across quintiles). Only the OR for the highest quintile, corresponding to 25-hydroxyvitamin D levels higher than 99.1 nmol/L, was significantly different from 1.00 (OR, 0.38; 95% confidence interval, 0.19-0.75; P = .006). The inverse relation with multiple sclerosis risk was particularly strong for 25-hydroxyvitamin D levels measured before age 20 years. Among blacks and Hispanics (109 cases, 218 controls), who had lower 25-hydroxyvitamin D levels than whites, no significant associations between vitamin D and multiple sclerosis risk were found.

Conclusion The results of our study suggest that high circulating levels of vitamin D are associated with a lower risk of multiple sclerosis.

×